SBIR/STTR Research Award

Targeting Oral Biofilms with 2-Aminoimidazole/Triazole Conjugates

Award identifier 28f00d9fbe864b0e350d48787c534b495d2a29260275463cedc71462712364c5Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$251,837

Program and phase

SBIR · Phase I

Award year

2010

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AGILE SCIENCES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
L9UJBZEVVDM1
Solicitation number
PHS2010-2
Topic code
NIDCR

Research abstract

DESCRIPTION (provided by applicant): Dental caries, or tooth decay, affects hundreds of millions of people each year, and is second only to the common cold in its prevalence world-wide. New therapeutics to aid in the prevention of dental caries would represent a significant advancement in oral health care. Caries is caused by acid-producing bacteria in the presence of carbohydrates, and these bacteria are particularly difficult to eradicate due to their ability to form biofilms, or plaque. While tooth brushing and biocide-containing mouthwash have reduced the occurrence of and severity of dental caries, these treatments cannot completely eradicate biofilms of the undesired bacteria, and so dental caries remains a significant medical problem. An ideal treatment for dental caries would be the selective elimination of pathogenic bacteria from plaque. Dr. Christian Melander's Research Group at North Carolina State University has developed non-toxic molecules that are active toward selectively inhibiting and dispersing bacterial biofilms. In this proposal, Agile Sciences will collaborate with the Melander Group to synthesize analogues of 2-aminoamidizole triazole (2-AIT) molecules developed in the Melander Lab and then to screen these compounds to identify those that selectively inhibit Streptococcus mutans biofilms. S. mutans has been strongly associated with the etiology of dental caries, and the formation of tenacious biofilm by S. mutans is a key virulent determinant in the disease process. Furthermore, the proposed work aims to identify molecules that inhibit and disperse S. mutans while not affecting the biofilm formation by oral commensal bacteria, S. sanguinis and S. gordonii. Based on Agile Sciences and the Melander Group's previous success and substantial experience in 1) tuning molecules to selectively inhibit and disperse biofilms, and 2) analogue synthesis utilizing a variety of synthetic and combinatorial techniques, it is anticipated that a large number of compounds with high probability of showing selective activity toward S. mutans biofilms will be screened over the time-frame of this Phase I STTR study. The specific aims of this proposal are: Specific Aim #1: Synthesize a diverse library of 2-AIT derivatives. Specific Aim #2: Assay 2-AIT derivatives for anti-biofilm activity using high-throughput screening under static conditions. Specific Aim #3: Examine the effects of 2-AIT derivatives on biofilm formation using a flow-cell system under shear force conditions. Specific Aim #4: To screen lead Compounds for toxicity. PUBLIC HEALTH RELEVANCE: The proposed study aims to develop a novel approach for treating dental caries, or tooth decay. Dental caries is caused by an elevated ratio of pathogenic to beneficial bacteria in the oral cavity. This work describes the development of molecules that may selectively release the pathogenic bacteria from plaque while not affecting the beneficial bacteria.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

15 SBIR/STTR records share this UEI (2009–2016). Reported award amounts total $8,631,717. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.